Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients’ lives.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $80M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
| 04.08.2023 | Internatio... | ibtplc.com |
| 08.11.2020 | Sofinnova ... | sofinnova.... |
| 19.01.2021 | Abingworth... | abingworth... |
| 23.01.2021 | Longitude ... | longitudec... |
| 10.07.2021 | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.01.2021 | Series C | $80M | - |
Mentions in press and media 8
| Date | Title | Description |
| 10.03.2026 | Vertex passes key test in quest to treat kidney diseases | Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company’s plan to expand into kidney disease. Vertex has faced questions about how it would div... |
| 08.12.2021 | Vera Bradley, Inc. announces an Equity Buyback for $50 million worth of its shares. | Vera Bradley, Inc. (NasdaqGS:VRA) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its shares. The repurchase program is valid till December 2024. |
| 20.04.2021 | Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer | |
| 25.01.2021 | Startup targets orphan kidney disease with former Merck drug | Photo: CaptureTheWorld, Getty Images Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more u... |
| 22.01.2021 | Vera Therapeutics Launches with $80M in Series C | SOUTH SAN FRANCISCO, CA, Vera Therapeutics announced its launch backed by $80 million Series C financing led by Abingworth. >> Click here for more funding data on Vera Therapeutics >> To export Vera Therapeutics funding data... |
| 19.01.2021 | We are pleased to announce Vera Therapeutics has launched with an $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease | - |
| 19.01.2021 | Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease | |
| - | Startup targets orphan kidney disease with former Merck drug | Backed by $80 million in Series C funding, Vera Therapeutics is targeting a chronic kidney disease with its first drug candidate, atacicept, a product the company licensed from Merck KGaA. Based in South San Francisco, Vera hopes to launch ... |